Items tagged with Treatment
Experts identify clinical standards for adverse effects to TB treatment (post)
A panel of 65 global experts have identified eight clinical standards for the management of adverse effects during treatment for tuberculosis (TB).
Study demonstrates efficacy of new short-term resistant TB treatment (post)
Tuberculosis (TB) disproportionately affects vulnerable populations including those with limited economic resources, HIV patients, those whose diet is deficient in nutrients and others. Resistant TB (MDR TB) does not respond to first line medications and is difficult to treat, requiring long regimens of 15-20 months that are associated with significant side effects and poor outcomes.
Webinar: Shortened TB regimen implementation challenges, and the 1/4/6x24 Campaign (post)
Socios En Salud Centro de Salud Global and partners will host a webinar on 3 August 2023 highlighting the 1/4/6x24 Campaign, examining the experience of the Dominican Republic in rolling out WHO-recommended shorter TB preventive therapy and treatment regimens, with perspectives from the World Health Organization (WHO), the Ministry of Health, civil society, and Dr. Carole Mitnick presenting on the 1/4/6x24 Campaign. The webinar will be offered with Spanish-English simultaneous interpretation.
PAN-TB collaboration announces the start of a Phase 2 clinical trial to evaluate two novel TB treatment regimens (post)
Public-private partnership launched a first-of-its-kind phase 2b/c trial to evaluate two novel tuberculosis drug regimens with the potential to treat all forms of active pulmonary TB
TB Alliance announces partnership with Remington Pharmaceuticals to commercialize new therapy for drug-resistant forms of TB in Pakistan (post)
NEW YORK (August 10, 2023)—Non-profit drug developer TB Alliance has granted Remington Pharmaceutical Industries (Pvt.) Ltd. a non-royalty bearing license to market the anti-tuberculosis (TB) medicine pretomanid as part of the all-oral, six-month BPaL and BPaLM regimens for treatment of drug-resistant TB (comprised of bedaquiline, pretomanid, and linezolid, with or without moxifloxacin). Pakistan ranks third among countries designated by the World Health Organization as having a high burden of drug-resistant TB. Remington has agreed to develop, manufacture, and commercialize pretomanid in Pakistan and the collaboration may extend to other countries in the future.
Higher dose and shorter TB treatment proven safe for patients (post)
A higher dose and shorter treatment time of a cornerstone tuberculosis (TB) drug has proven to be safe for patients, according to a clinical trial led by researchers at St George's, University of London. Results have been published in NEJM Evidence.
Community perspective on child-friendly medications for drug-resistant TB: importance, priorities and advocacy (post)
An editorial, published in the International Journal of Tuberculosis and Lung Disease, elaborates on the need to advance child-friendly medications to treat pediatric drug-resistant TB.
Drug shortage shows Modi’s TB eradication dream needs more than just ambition (post)
In 2018, India articulated its noble ambition to eliminate TB by 2025, five years before the global target. But news reports show we aren’t even close to that goal.
Kyrgyzstan, Ukraine, and Uzbekistan update national guidelines for drug-resistant TB treatment to advance national rollout of three-drug, six-month regimen (post)
PRETORIA (September 18, 2023)—Kyrgyzstan, Ukraine, and Uzbekistan – participants in the LIFT-TB project – have updated their National Tuberculosis (TB) Clinical Guidelines to endorse the all-oral, six-month BPaL/M (bedaquiline + pretomanid + linezolid ± moxifloxacin) regimen(s) as the national standard for treating most patients with drug-resistant tuberculosis (DR-TB).
Johnson & Johnson under investigation in South Africa over 'excessive' drug prices (post)
U.S.-based pharmaceuticals company Johnson & Johnson is being investigated in South Africa for allegedly charging “excessive” prices for a key tuberculosis drug, the country's antitrust regulator said Friday (15 September).
Page 71 of 108 · Total posts: 0
←First 70 71 72 Last→